Biotech Market News
-
Karyopharm Plans August FDA Filing for Selinexor Combination
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration in August 2026 for selinexor in combination with ruxolitinib as a treatment for myelofibrosis. The company said it will seek accelerated approval following discussions with the FDA.…
-
HLS Secures Broad Private Coverage for NILEMDO Across Canada
HLS Therapeutics Inc. (TSX: HLS), a specialty pharmaceutical company focused on cardiovascular and psychiatric treatments, has expanded Canadian reimbursement access for NILEMDO, its oral cholesterol-lowering medication. The company said it has secured reimbursement agreements with Canada’s largest private payers, which it estimates represent approximately 80% of privately insured Canadians. Most patients covered by those plans…
-
Solventum Explores Separating Its Health Information Systems
Solventum (NYSE: SOLV) announced on August 5 that it intends to separate its Health Information Systems (HIS) business, the healthcare-software unit that handles medical coding, revenue-cycle management, and clinician-productivity software for hospitals and health systems. The company has not committed to a specific structure yet: it says it will evaluate options including a spinoff into…
-
What Is Short Interest in Biotech Stocks? Reading a Key Sentiment Indicator
Ahead of a major biotech catalyst — a PDUFA date, a Phase 3 readout — one of the data points sophisticated investors check is short interest: how many shares of the stock are currently sold short, representing bets that the price will fall. Biotech stocks, with their binary catalysts and dramatic potential price swings, attract…
-
BWXT Sells Medical Isotopes Business to Nordic Capital for $800M
BWX Technologies, Inc. (NYSE: BWXT) announced on August 3 that it has entered a definitive agreement to sell its medical business, comprising BWXT Medical and Kinectrics’ stable medical isotopes unit, to Nordic Capital, a European private equity firm with a healthcare focus, in a transaction valued at up to $800 million. For investors, the deal…
-
What Is Market Capitalization in Biotech? How to Read a Company’s Size and Stage
Market capitalization is one of the first numbers every investor learns, and one of the most frequently misinterpreted in the biotech context. In most industries, a company’s market cap reflects its current business — its revenue, profitability, and near-term growth trajectory. In biotech, especially for clinical-stage companies, market cap reflects something fundamentally different: the market’s…
-
What Is a Biotech IPO? How Clinical-Stage Companies Go Public and What Investors Should Know
The biotech IPO market is one of the most distinctive segments of the public equity landscape. Clinical-stage biotech companies routinely go public with no revenue, no approved products, and development timelines measured in years — and retail investors who understand how the IPO process works and what to look for in a biotech prospectus are…
-
What Is Dilution in Biotech? How Capital Raises Affect Shareholders
Dilution is one of the most frequently recurring events in the world of clinical-stage biotech investing, and one of the most misunderstood by retail investors encountering it for the first time. When a biotech company raises capital by issuing new shares, the total share count increases — which means each existing shareholder now owns a…
-
What Is a Biotech Licensing Deal? How Pharma Partnerships Work for Investors
A licensing deal announcement can be one of the most significant catalysts a clinical-stage biotech company produces. When a small biotech licenses rights to one of its drug programs to a large pharmaceutical company, the deal typically brings an immediate cash payment, validation from a sophisticated buyer who has conducted its own due diligence, and…
-
What Is a Binary Event in Biotech? High-Stakes Catalysts Explained
Few events in the financial markets generate the kind of violent, same-day price moves that biotech binary events produce. A Phase 3 trial result, an FDA approval decision, or an AdCom vote can send a stock up 80% or down 70% before most investors have finished their morning coffee. The term ‘binary event’ is one…